These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30848192)

  • 21. Intestinal fibrosis: ready to be reversed.
    Latella G; Rieder F
    Curr Opin Gastroenterol; 2017 Jul; 33(4):239-245. PubMed ID: 28402994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autophagy Stimulation as a Potential Strategy Against Intestinal Fibrosis.
    Cosin-Roger J; Canet F; Macias-Ceja DC; Gisbert-Ferrándiz L; Ortiz-Masiá D; Esplugues JV; Alós R; Navarro F; Barrachina MD; Calatayud S
    Cells; 2019 Sep; 8(9):. PubMed ID: 31540207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for Treatment of Inflammatory Bowel Disease Complications with Fibrosis.
    Goffin L; Fagagnini S; Vicari A; Mamie C; Melhem H; Weder B; Lutz C; Lang S; Scharl M; Rogler G; Chvatchko Y; Hausmann M
    Inflamm Bowel Dis; 2016 Sep; 22(9):2041-57. PubMed ID: 27542125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can we prevent, reduce or reverse intestinal fibrosis in IBD?
    Latella G; Sferra R; Speca S; Vetuschi A; Gaudio E
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1283-304. PubMed ID: 23740440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrotic Strictures in Crohn's Disease: Mechanisms and Predictive Factors.
    Mager R; Roda G; Shalaby MK; Vetrano S
    Curr Drug Targets; 2021; 22(2):241-251. PubMed ID: 33081672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crohn's disease related strictures in cross-sectional imaging: More than meets the eye?
    Sleiman J; Chirra P; Gandhi NS; Baker ME; Lu C; Gordon IO; Viswanath SE; Rieder F;
    United European Gastroenterol J; 2022 Dec; 10(10):1167-1178. PubMed ID: 36326993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can we influence fibrosis in Crohn's disease?
    Assche GV
    Acta Gastroenterol Belg; 2001; 64(2):193-6. PubMed ID: 11475134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating fibrocytes and Crohn's disease.
    Sahebally SM; Burke JP; Chang KH; Kiernan MG; O'Connell PR; Coffey JC
    Br J Surg; 2013 Nov; 100(12):1549-56. PubMed ID: 24264775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic modulation during intestinal fibrosis.
    Bos S; Laukens D
    J Dig Dis; 2020 Jun; 21(6):319-325. PubMed ID: 32406133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease.
    Danese S; Bonovas S; Lopez A; Fiorino G; Sandborn WJ; Rubin DT; Kamm MA; Colombel JF; Sands BE; Vermeire S; Panes J; Rogler G; D'Haens G; Peyrin-Biroulet L
    Gastroenterology; 2018 Jul; 155(1):76-87. PubMed ID: 29601825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel mechanisms and clinical trial endpoints in intestinal fibrosis.
    Wang J; Lin S; Brown JM; van Wagoner D; Fiocchi C; Rieder F
    Immunol Rev; 2021 Jul; 302(1):211-227. PubMed ID: 33993489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenesis of fibrostenosing Crohn's disease.
    Li J; Mao R; Kurada S; Wang J; Lin S; Chandra J; Rieder F
    Transl Res; 2019 Jul; 209():39-54. PubMed ID: 30981697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intestinal fibrosis in Crohn's disease: role of microRNAs as fibrogenic modulators, serum biomarkers, and therapeutic targets.
    Lewis A; Nijhuis A; Mehta S; Kumagai T; Feakins R; Lindsay JO; Silver A
    Inflamm Bowel Dis; 2015 May; 21(5):1141-50. PubMed ID: 25636122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative apparent diffusion coefficient (ADC) values as an imaging biomarker for fibrosis in pediatric Crohn's disease: preliminary experience.
    Kovanlikaya A; Beneck D; Rose M; Renjen P; Dunning A; Solomon A; Sockolow R; Brill PW
    Abdom Imaging; 2015 Jun; 40(5):1068-74. PubMed ID: 25248794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intestinal myofibroblast TRPC6 channel may contribute to stenotic fibrosis in Crohn's disease.
    Kurahara LH; Sumiyoshi M; Aoyagi K; Hiraishi K; Nakajima K; Nakagawa M; Hu Y; Inoue R
    Inflamm Bowel Dis; 2015 Mar; 21(3):496-506. PubMed ID: 25647156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum biomarkers of fibrostenotic Crohn's disease: Where are we now?
    He JS; Tan JY; Li XZ; Feng R; Xiong SS; Lin SN; Qiu Y; Mao R
    J Dig Dis; 2020 Jun; 21(6):336-341. PubMed ID: 32496631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Targeting of Intestinal Fibrosis in Crohn's Disease.
    Santacroce G; Lenti MV; Di Sabatino A
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease.
    Lovisa S; Genovese G; Danese S
    J Crohns Colitis; 2019 Apr; 13(5):659-668. PubMed ID: 30520951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease.
    Rieder F; Bettenworth D; Ma C; Parker CE; Williamson LA; Nelson SA; van Assche G; Di Sabatino A; Bouhnik Y; Stidham RW; Dignass A; Rogler G; Taylor SA; Stoker J; Rimola J; Baker ME; Fletcher JG; Panes J; Sandborn WJ; Feagan BG; Jairath V
    Aliment Pharmacol Ther; 2018 Aug; 48(3):347-357. PubMed ID: 29920726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent.
    Suenaert P; Bulteel V; Vermeire S; Noman M; Van Assche G; Rutgeerts P
    Inflamm Bowel Dis; 2005 Jul; 11(7):667-73. PubMed ID: 15973122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.